Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.
Dennis Slamon, MD, PhD, UCLA Health, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer (NCT03701334), discussed the study's broad population and potential payer reactions. Interim findings from the study were presented at the 2023 Annual Meeting of the American Society of Clinical Oncology.
Transcript
What elements make this trial different from other studies in early breast cancer?
The biggest element that differentiates this trial from other trials is the inclusion of a broader population of these patients—in other words, patients with node-negative disease, patients with lower-stage disease. Some of the trials were really focused on high-risk patients. Are those the only patients that can benefit from the drug? Patients who have lower risk but are still at risk for having—as I said, 30% will have a recurrence 2 or 3 decades out—can those patients be benefited? Well, the trial is including those patients in the study.
If this treatment approach is used in real-world settings, do you feel payers will see value in the improved safety profile vs the longer treatment duration?
My sense is that it all depends on the data. If the data are strong enough and there is a survival advantage, I think payers would be hard pressed not to provide reimbursement for the drug. Clearly, drug pricing is important. And it should be rational in terms of what the drug costs are. But if it provides real value and really makes an impact both on quality of life and life itself, I think those drugs should be paid for.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More